- Home
- KALA vs ENLV Comparison
KALA vs ENLV Comparison
Compare KALA & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- ENLV
- Stock Information
- Founded
- KALA 2009
- ENLV 2005
- Country
- KALA United States
- ENLV Israel
- Employees
- KALA N/A
- ENLV N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- ENLV Health Care
- Exchange
- KALA Nasdaq
- ENLV Nasdaq
- Market Cap
- KALA 31.3M
- ENLV 25.9M
- IPO Year
- KALA 2017
- ENLV 1995
- Fundamental
- Price
- KALA $5.92
- ENLV $1.24
- Analyst Decision
- KALA Strong Buy
- ENLV Strong Buy
- Analyst Count
- KALA 2
- ENLV 2
- Target Price
- KALA $15.00
- ENLV $9.50
- AVG Volume (30 Days)
- KALA 31.1K
- ENLV 432.1K
- Earning Date
- KALA 11-12-2024
- ENLV 11-29-2024
- Dividend Yield
- KALA N/A
- ENLV N/A
- EPS Growth
- KALA N/A
- ENLV N/A
- EPS
- KALA N/A
- ENLV N/A
- Revenue
- KALA N/A
- ENLV N/A
- Revenue This Year
- KALA N/A
- ENLV N/A
- Revenue Next Year
- KALA N/A
- ENLV N/A
- P/E Ratio
- KALA N/A
- ENLV N/A
- Revenue Growth
- KALA N/A
- ENLV N/A
- 52 Week Low
- KALA $4.21
- ENLV $0.81
- 52 Week High
- KALA $9.25
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- KALA 41.69
- ENLV 53.08
- Support Level
- KALA $5.67
- ENLV $1.16
- Resistance Level
- KALA $6.23
- ENLV $1.24
- Average True Range (ATR)
- KALA 0.31
- ENLV 0.10
- MACD
- KALA -0.07
- ENLV 0.01
- Stochastic Oscillator
- KALA 21.55
- ENLV 56.68
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.